您的购物车当前为空
别名 恩美曲妥珠单抗, Trastuzumab emtansine, T-DM1
Trastuzumab emtansine(Ado-Trastuzumab emtansine)是一种抗体–药物偶联物,将曲妥珠单抗对 HER2 的靶向抗肿瘤特异性与微管抑制剂 DM1 的强细胞毒活性相结合,可将细胞毒性载荷选择性递送至 HER2 表达细胞内,Trastuzumab emtansine 广泛应用在晚期乳腺癌模型中的转化医学和作用机制研究。


为众多的药物研发团队赋能,
让新药发现更简单!
Trastuzumab emtansine(Ado-Trastuzumab emtansine)是一种抗体–药物偶联物,将曲妥珠单抗对 HER2 的靶向抗肿瘤特异性与微管抑制剂 DM1 的强细胞毒活性相结合,可将细胞毒性载荷选择性递送至 HER2 表达细胞内,Trastuzumab emtansine 广泛应用在晚期乳腺癌模型中的转化医学和作用机制研究。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 3,980 | 现货 | |
| 5 mg | ¥ 8,460 | 现货 | |
| 10 mg | ¥ 11,300 | 现货 | |
| 25 mg | ¥ 16,900 | 现货 | |
| 50 mg | ¥ 22,800 | 现货 |
| 产品描述 | Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody–drug conjugate that combines the HER2-targeted antitumor specificity of trastuzumab with the potent cytotoxic activity of the microtubule inhibitor DM1, Trastuzumab emtansine enables selective intracellular delivery of the cytotoxic payload to HER2-expressing cells and supporting translational and mechanistic research in advanced breast cancer models. |
| 体外活性 | Trastuzumab emtansine (2 μg/mL; 3 d) significantly inhibits the proliferation of epithelial ovarian cancer (EOC) cells[2]. |
| 体内活性 | 方法:在注射 OVA10 细胞的 CB-17/SCID 小鼠中,每周静脉注射Trastuzumab emtansine15 mg/kg,每周 3–5 次,持续 3 周。 |
| 别名 | 恩美曲妥珠单抗, Trastuzumab emtansine, T-DM1 |
| 反应种属 | Human |
| 应用 | ELISA FACS Functional assay |
| 抗体种类 | Monoclonal |
| 缓冲液 | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| 内毒素 | <1.0 EU/mg |
| 同型 | IgG1 |
| Uniprot ID | |
| 靶点 | HER2 |
| 分子式 | N/A |
| CAS No. | 1018448-65-1 |
| Smiles | [Trastuzumab emtansine] |
| 存储 | |
| 溶解度信息 | DMSO: 160 mg/mL, Sonication is recommended. |
对于不同动物的给药剂量换算,您也可以参考 更多